Literature DB >> 11023674

Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus.

S Narumi1, T Takeuchi, Y Kobayashi, K Konishi.   

Abstract

IFN-inducible protein-10 (IP-10) is supposed to act as a specific chemoattractant for Th(1)cells. Since Th(1)cells and IFN-gamma are shown to be important for developing systemic lupus erythematosus (SLE), we examined the relationship between serum IP-10 levels and the disease activity. Serum IP-10 levels were markedly increased in the SLE patients depending on the level of disease activity, whereas not in the patients with rheumatoid arthritis (RA). On the other hand, serum MCP-1 levels were increased to a similar extent both in RA and inactive SLE patients, and a little more elevated in active SLE patients. Serum IP-10 levels in SLE patients correlated positively and negatively with levels of anti-DNA antibody and complements, respectively, whereas MCP-1 levels correlated less or not at all. These results suggest that serum IP-10 levels could be a good indicator for the activity of SLE and that IP-10 could play an important immunological role in SLE. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023674     DOI: 10.1006/cyto.2000.0757

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  47 in total

Review 1.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

2.  Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.

Authors:  Aniko Rentka; Jolan Harsfalvi; Gabriella Szucs; Zoltan Szekanecz; Peter Szodoray; Krisztina Koroskenyi; Adam Kemeny-Beke
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia.

Authors:  Shu-Fen Zhou; Ji Ma; Hui-Ting Qu; Zong-Tang Liu; Wei-Dong He; Juan-Dong Wang; Ai-Xia Dou; Ni Zhang; Jun-Li Liu; Cheng-Shan Guo; Yan Shi; Ming Hou; Jun Peng
Journal:  J Clin Immunol       Date:  2013-03-14       Impact factor: 8.317

4.  Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.

Authors:  Jung-Yoon Choe; Seong-Kyu Kim
Journal:  Inflamm Res       Date:  2016-02-26       Impact factor: 4.575

5.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

Authors:  Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

6.  Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.

Authors:  K O Kong; A W Tan; B Y H Thong; T Y Lian; Y K Cheng; C L Teh; E T Koh; H H Chng; W G Law; T C Lau; K P Leong; B P Leung; H S Howe
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

7.  A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE.

Authors:  Matilda W Nicholas; Mary Anne Dooley; Susan L Hogan; Jennifer Anolik; John Looney; Ingnacio Sanz; Stephen H Clarke
Journal:  Clin Immunol       Date:  2008-02       Impact factor: 3.969

8.  Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis.

Authors:  Ahmed El-Gohary; Ann Hegazy; Mostafa Abbas; Noha Kamel; Samah Ismail Nasef
Journal:  J Clin Lab Anal       Date:  2016-05-17       Impact factor: 2.352

9.  Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.

Authors:  Bo Chen; Qin Zong; Ricardo Cibotti; Chad Morris; Juana Castaneda; Brian Naiman; Derong Liu; Anna Glodek; Gary P Sims; Ronald Herbst; Stephen K Horrigan; Peter A Kiener; Dan Soppet; Anthony J Coyle; Laurent Audoly
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

10.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Authors:  Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2009-09-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.